ULG Anesthésie Vétérinaire

Julien presented his work on improving oxygenation of horses during anaesthesia at the FARAH day.

https://www.youtube.com/watch?v=_XwKc29q-Ck&t=138s

La Belgique, les Pays-Bas et l'Allemagne vont-ils accueillir le Téléscope Einstein ? Le futur télescope européen Einstein aura pour objectif de détecter les ondes gravitationnelles pour observer l’univers. Un rôle qu'il pourrait remplir à la ...

https://www.sciencedirect.com/science/article/pii/S1467298722000113?dgcid=coauthor

Effects of perineural dexmedetomidine combined with ropivacaine on postoperative methadone requirements in dogs after tibial plateau levelling osteotomy: a two-centre study To evaluate the efficacy of a perineural injection of dexmedetomidine combined with ropivacaine for reducing postoperative methadone requirements in d…

Dear Friends,

We would like to announce the start of our free webinar series, and welcome you to our first webinar, which will take place on Wednesday 2nd of February at 19:00 CET.

ESAVS Anaesthesia & Emergency Critical Care study program

Program Director / Principal Course Master (ESAVS Anaesthesia & Pain Management):

Priv.-Doz. Dr. Eva Eberspächer-Schweda, FTA, Dipl. ACVAA

Topic:

Everything you always wanted to know about Ketamine! - Why Ketamine is such a good friend in small animal anaesthesia.

Overview:

Ketamine is a drug commonly used in anaesthesia. However, it has a bad reputation among many veterinarians because side effects may appear, especially if it is not used correctly. At low doses, ketamine has an anti-hyperalgesic effect and, although it is not a scheduled drug, it can provide pronounced somatic analgesia. It stabilises the circulation, reduces arrhythmias and has many other positive effects.

In this webinar, you will learn the proper use of this valuable anaesthetic drug and how to use it correctly in small animals. By using it the right way, the well-known and feared side effects can be avoided and you and your patient can benefit from the positive properties.

Register in advance for this webinar, as the places are limited:

https://esavs.zoom.us/webinar/register/WN_PpJoyvw9ShatOTBINIvJzQ

After registering, you will receive a confirmation email containing information about joining the webinar.

This webinar will not be recorded, therefore we encourage you to join live!

SOLENSIA® is the first injectable monoclonal antibody (mAb) licensed for alleviation of pain associated with osteoarthritis (OA) in catsSOLENSIA® works as a monthly treatment targeting Nerve Growth Factor (NGF), a key player in OA painEuropean Commission Marketing Authorization for a similar product in dogs, LIBRELA®, was received in November 2020

The resource cannot be found.